Abstract
Tabled 1Capsule Summary•Melasma remains a therapeutic challenge.•Retrospective analysis suggests that oral tranexamic acid might be a worthwhile adjunct in the treatment of refractory melasma.•A detailed history to exclude risk factors of thromboembolism, stroke, or heart disease is mandatory before initiating therapy.How did this article change the practice of dermatology?This study shows an 89.7% improvement in melasma with oral tranexamic acid, which is very high, considering the disease is often highly resistant to therapy. Clotting risk is elevated, and screening is mandatory before initiation.1Lee H.C. Thng T.G.S. Goh C.L. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis.J Am Acad Derm. 2016; 75: 385-392Abstract Full Text Full Text PDF PubMed Scopus (100) Google Scholar Open table in a new tab
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
